Back to results
US 2007/0166279 A1Published application
Method for modulating hla class ii tumor cell surface expression with a cytokine mixture
OwnerEyal Talorinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerEyal Talorinventor
Estimating the term…
A method for altering the composition of tumor infiltrating mononuclear cells, increasing CD4+/CD8+ ratio, increasing tumor stroma/epithelial ratio and modulating HLA (Human Leukocyte Antigen) class II expression on a tumor cell surface with a serum-free and mitogen-free mixture having specific cytokine ratios from the group of IL-1β, TNF-α, IFN-γ, GM-CSF, and Interleukin-2 (IL-2) with specific ratios of IL-1β, TNF-α, IFN-γ, GM-CSF to IL-2, respectively. The serum-free and mitogen-free mixtures comprised of cytokine ratios include Leukocyte Interleukin Injection (LI) or Multikine®, which can be further used alone or in combination with other drugs for the treatment of cancer thereby increasing the success of cancer treatment and the disease free survival of cancer patients.
A method for modulating HLA Class II tumor cell surface expression, which comprises administering to a patient in need thereof a serum-free and mitogen-free cytokine mixture comprised of specific ratios of cytokines selected from the group of IL-1β, TNF-α, IFN-γ, GM-CSF, Interleukin-2 (IL-2) where the specific ratios of IL-1β, TNF-α, IFN-γ, GM-CSF to IL-2 are:
Dependencies are inferred from the claim text.